4//SEC Filing
Mattes Glenn R. 4
Accession 0001213900-20-045177
CIK 0001733413other
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 4:05 PM ET
Size
9.7 KB
Accession
0001213900-20-045177
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2020-12-23$2.50/sh+30,000$75,000→ 40,000 total - Sale
Common Stock
2020-12-23$15.33/sh−30,000$459,900→ 10,000 total - Exercise/Conversion
Stock Options (Right to Buy)
2020-12-23−30,000→ 1,074,227 totalExercise: $2.50From: 2019-05-01Exp: 2028-05-01→ Common Stock (30,000 underlying)
Holdings
- 10,000(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effect pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]200,000 shares of the option vested and became exercisable on May 1, 2019.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001568678
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 4:05 PM ET
- Size
- 9.7 KB